Ibandronate: A Comparison of Oral Daily Dosing Versus Intermittent Dosing in Postmenopausal Osteoporosis
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
The objective of this study was to compare efficacy and safety of continuous versus intermittent oral dosing of ibandronate. Two hundred forty women aged 55–75 years with postmenopausal osteoporosis were randomized to active treatment or placebo. Similar total doses of ibandronate were provided by treatment regimens with either continuous 2.5 mg of ibandronate daily (n = 81) or intermittent 20 mg of ibandronate every other day for the first 24 days, followed by 9 weeks without active drug (n = 78). The placebo group (total, n = 81) was crossed over after 12 months to receive either continuous (n = 37) or intermittent ibandronate (n = 35). By 24 months, bone mineral density (BMD) had increased significantly relative to baseline in both active treatment groups. The continuous and intermittent groups showed statistically equivalent increases in lumbar spine BMD of +5.64% (±0.53) and +5.54% (±0.53) and in total hip of +3.35% (±0.40) and +3.41% (±0.40), respectively (per protocol population). Biochemical markers of bone turnover decreased significantly in both treatment groups. The level of marker suppression was similar, although the intermittent group displayed, as expected, more fluctuation over the treatment period. The frequency of adverse events was similar in the treatment groups. In conclusion, the intermittent and continuous regimens showed equivalent changes in BMD and bone turnover. These results confirm previous preclinical findings indicating that the efficacy of ibandronate depends on the total oral dose given rather than on the dosing schedule. This supports development of new flexible dosing regimens targeted to minimize the frequency of dosing, which are expected to improve convenience and lead to enhanced long-term patient compliance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
BM 21.0955, a potent new bisphosphonate to inhibit bone resorption.
Mühlbauer, R. C., Bauss, F., Schenk, R., Janner, M., Bosies, E., Strein, K., & Fleisch, H. (1991) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650060915 · Cited by 239
Cited by
Interventions for enhancing medication adherence
Nieuwlaat, R., Wilczynski, N., Navarro, T., Hobson, N., Jeffery, R., Keepanasseril, A., Agoritsas, T., Mistry, N., Iorio, A., Jack, S., et al. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000011.pub4 · Cited by 2,945
Interventions for enhancing medication adherence
Haynes, R. B., Ackloo, E., Sahota, N., McDonald, H. P., & Yao, X. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000011.pub3 · Cited by 1,244
Chesnut, C. H., Skag, A., Christiansen, C., Recker, R., Stakkestad, J. A., Hoiseth, A., Felsenberg, D., Huss, H., Gilbride, J., Schimmer, R. C., et al. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040325 · Cited by 1,229
Self-citationInterventions for enhancing medication adherence
Haynes, R., Yao, X., Degani, A., Kripalani, S., Garg, A., & McDonald, H. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000011.pub2 · Cited by 517
Miller, P. D., Mcclung, M. R., Macovei, L., Stakkestad, J. A., Luckey, M., Bonvoisin, B., Reginster, J.-Y., Recker, R. R., Hughes, C., Lewiecki, E. M., et al. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.050313 · Cited by 333
Metadata
- Authors
- Riis, B. J., Ise, J., Von Stein, T., Bagger, Y., & Christiansen, C.
- Venue
- Journal of Bone and Mineral Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2001-10-01
- Volume
- 16
- Issue
- 10
- Pages
- 1871-1878
- ISSN
- 0884-0431 (ISSN-L)
- 1523-4681
- OpenAlex
- W1971046106
- Cited by
- 100
- References
- 1
- FWCI
- 10.48
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Ibandronate: A Comparison of Oral Daily Dosing Versus Intermittent Dosing in Postmenopausal Osteoporosis. https://app.cochat.ai/papers/10.1359/jbmr.2001.16.10.1871
- The paper
- Riis, B. J., Ise, J., Von Stein, T., Bagger, Y., & Christiansen, C. (2001). Ibandronate: A Comparison of Oral Daily Dosing Versus Intermittent Dosing in Postmenopausal Osteoporosis. Journal of Bone and Mineral Research. https://doi.org/10.1359/jbmr.2001.16.10.1871
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.